A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
Conditions: Non Small Cell Lung Cancer Metastatic; ALK Gene Mutation Interventions: Drug: Lorlatinib Sponsors: Centro di Riferimento Oncologico - Aviano Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study